Biobusiness Briefs | Published:

Trial watch

The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

Nature Reviews Drug Discovery volume 17, pages 854855 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Acknowledgements

The authors thank D. Patel from IQVIA for supporting this report.

Author information

Affiliations

  1. Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

    • Jun Tang
    • , Jia Xin Yu
    •  & Vanessa M. Hubbard-Lucey
  2. IQVIA, Durham, NC, USA.

    • Svetoslav T. Neftelinov
    • , Jeffrey P. Hodge
    •  & Yunqing Lin

Authors

  1. Search for Jun Tang in:

  2. Search for Jia Xin Yu in:

  3. Search for Vanessa M. Hubbard-Lucey in:

  4. Search for Svetoslav T. Neftelinov in:

  5. Search for Jeffrey P. Hodge in:

  6. Search for Yunqing Lin in:

Competing interests

JT, JXY, and VHL are employees of Cancer Research Institute and claim no conflicts of interests.

STN, JPH, YL and DP are employees of IQVIA and claim no conflicts of interests.

Corresponding author

Correspondence to Jun Tang.

Supplementary information

PDF files

  1. 1.

    Supplementary information

    Supplementary information S1 (figure)

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2018.210

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing